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Abstract: Recently, multiple C1 inhibitor (C1-INH) replacement products have been approved 
for the treatment of hereditary angioedema (HAE). This review summarizes HAE and its 
current treatment modalities and focuses on findings from bench to bedside trials of a new 
C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replace-
ment products because it is produced from transgenic rabbits rather than derived from human 
plasma donors, which can potentially allow an unlimited source of drug without any concern 
of infectious transmission. The clinical trial data generated to date indicate that conestat alfa is 
safe and effective for the treatment of acute HAE attacks.
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Hereditary angioedema
Clinical presentation
Hereditary angioedema (HAE) is a rare disorder characterized by recurrent attacks of 
swelling that may involve the peripheral extremities (most common), intestines, trunk, 
genitalia, face, and upper respiratory tract. The frequency of attacks varies greatly, 
but can occur as often as several times a week. Time of onset, incidence, location, and 
severity of clinical manifestations also vary between individuals even within the same 
family.1 Mechanical trauma, infections, menstruation, pregnancy, oral contraceptives, 
and angiotensin-converting enzyme (ACE) inhibitors are examples of potential attack 
triggers.2–4 Edema is not accompanied by erythema, pruritus, or urticaria and it usually 
resolves over a couple of days.5 Abdominal complaints are the second most frequent 
manifestation. Abdominal symptoms include nausea, vomiting, colicky pain, and 
diarrhea.5–7 These symptoms have been misinterpreted as an acute abdomen leading to 
unnecessary surgery. Edema of the upper airway is the most dangerous manifestation 
of HAE. Asphyxiation resulting in airway obstruction is the leading cause of death.8 
Rarely, cerebral edema can develop with neurological symptoms. Pulmonary edema 
has not been reported as a common complication, presumably because bradykinin is 
effectively metabolized in the lung.9
epidemiology
The prevalence of HAE has been estimated to range from 1:10,000 to 1:50,000 persons 
in the United States (US).10 Fifty percent of initial attacks begin in the first decade of 
life (average age 11 years) and an additional 30% during the second decade of life. In 
undiagnosed HAE, the mortality rate can be as high as 30% to 50%.11,12Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Mechanism
Most HAE patients have either a quantitative (type I) or a 
functional (type II) defect in the C1 inhibitor (C1-INH), 
which is an important regulator of the complement, fibrin-
olytic, kallikrein–kinin, and coagulation pathways.13,14 For 
most HAE patients, inheritance is autosomal dominant, 
although 25% of cases can occur as the result of de novo 
mutations.15 However, in 5% of apparent HAE cases, no 
mutation of the C1-INH gene can be demonstrated.13 A third 
type of HAE, referred to as type III, characterized by nor-
mal quantitative and functional C1-INH levels and estrogen 
dependence, occurs more frequently in females. The original 
cases reported were associated with a missense mutation 
in Hagemann factor (Factor XII) although this observation 
has not been consistently observed in other cases of type 
III HAE.16
Diagnosis
Diagnosis may be suspected by taking a thorough history 
and physical examination. Typically there is a strong family 
history with the exception of those individuals who develop 
a spontaneous mutation later in life. Screening is performed 
by analysis of C4 levels, which are significantly reduced in 
HAE. In type I HAE, there is a quantitative decrease in serum 
C1-INH levels that are also functionally abnormal, whereas in 
type II HAE there is a normal or often elevated serum level 
of C1-INH but functionally reduced C1-INH activity.
Patients with type III HAE have normal quantitative and 
functional levels of C1-INH, but a strong family history of 
angioedema. This condition has been associated with a gain 
of function mutation in factor XII in some patients.
Genetic analysis can aid in prenatal diagnosis. However, 
in general, genetic studies are not required or necessary to 
make a diagnosis of HAE, as history, physical examination, 
and complement studies usually suffice. In the absence of 
a clear family history, up to 25% of HAE patients can have 
a spontaneous mutation but in these cases acquired angioe-
dema should be excluded by obtaining a C1q complement 
component.
Treatment
Standard treatments for other types of angioedema, includ-
ing epinephrine, corticosteroids, and H1 or H2 histamine 
receptor antagonists, are ineffective for HAE.17 Traditional 
therapies for HAE, including fresh frozen plasma (FFP), 
ε-aminocaproic acid, and danazol, may be efficacious but 
have a negative safety profile.1 Drugs currently under inves-
tigation or recently approved to treat HAE in the US can be 
divided into three categories: C1-INH replacement therapies; 
a kallikrein inhibitor and a bradykinin receptor 2 antagonist. 
The C1-INH replacement therapies can be further subdivided 
into plasma-derived products, which include Berinert P (CSL 
Behring) and Cinryze® (Viropharma) and a recombinant 
human C1-INH, conestat alfa (Rhucin® in US, Ruconest® 
in Europe; Pharming). Ecallantide (Kalbitor®; Dyax Cor-
poration) is a kallikrein inhibitor and icatibant (Firzyr®; 
Shire Pharmaceuticals) is a bradykinin receptor antagonist. 
Treatment of HAE includes: long-term prophylaxis with 
androgens (ie, danazol) or Cinryze and on-demand therapy 
with Berinert P, ecallantide and, when approved in the US, 
icatibant and conestat alfa.
Acute “on-demand” treatment
Traditionally, acute therapy for HAE in the US   consisted of 
FFP, antifibrinolytics or high-dose androgens. As   mentioned, 
drawbacks of using FFP include potential infection 
  transmission and worsening of acute symptoms after 
administration. For ε-aminocaproic acid there is only 
anecdotal evidence of its efficacy for acute attacks. The 
European experience with transexamic acid is more 
robust but this agent is not readily available in the US for 
  treatment of acute HAE attacks. Attenuated androgens are 
ineffective for acute treatment because their therapeutic 
effects are delayed for at least 1 to 2 days after they are 
started.1,18,36,37
Recently Berinert P and ecallantide have been approved 
for use of acute attack therapy in the US.
Short-term prophylaxis
Short-term prophylaxis for HAE should be initiated 
before any planned invasive procedure, including dental 
  procedures if the patient has a history of swelling with 
trauma.   Administration of FFP prophylaxis before trauma 
has been shown to decrease the risk of attack.33,34 Recently, 
a case involving a 51-year-old man with HAE who received 
Cinryze 1 hour before mitral valve reconstruction surgery 
requiring a cardiopulmonary bypass pump was reported. 
This case represented the first successful use of C1-INH 
as acute and prophylactic therapy in the US for a patient 
undergoing cardiac surgery requiring a cardiopulmonary 
bypass pump.35
Long-term prophylaxis
In patients with more than one attack a month or with a 
history of life-threatening laryngeal attacks, long-term 
  prophylaxis should be considered.11Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Specific treatments
Avoidance of triggers
Trauma, stress, infections, ACE inhibitors, and hormone 
replacement therapy has been associated with angioedema 
attacks and should be avoided if possible in HAE patients.3,5,18,19 
However, many patients with HAE have no recognizable 
triggers and no pre-aura that would indicate an eminent 
attack.
Attenuated androgens
Multiple studies demonstrate efficacy of androgens as 
long-term prophylaxis for HAE.9,20–22 These drugs are 
synthetic 17-α-alkylated androgens and include danazol, 
stanozolol, and oxandrolone.6,7 Originally thought to be 
effective by increasing hepatic synthesis of C1-INH, they 
have been shown to be effective for type II and type III 
HAE as well.9,20,23,24 Androgens have significant, common 
side effects including weight gain, menstrual irregularities, 
virilization, headache, myalgia, depression, acne, elevated 
liver function tests and cholesterol, and fatty liver. Other 
serious adverse events include myocardial infarction, stroke, 
acute pancreatitis, biliary hamartoma, liver cell adenoma, 
and hypertension.6,20,22,25
Antifibrinolytics
The antifibrinolytics, which include ε-aminocaproic acid 
and transexamic acid, are considered to be less effective for 
long-term prophylaxis than attenuated androgens but have 
been demonstrated to be effective for acute attacks.1,26,27 
The mechanism of action of antifibrinolytics is not well 
understood. Traditionally, they were used in situations when 
avoidance of attenuated androgen side effects was important, 
particularly in children.28 Major adverse effects include 
thrombosis and rhabdomyolysis.29,30
Fresh frozen plasma
FFP has been used successfully for acute HAE attacks but 
there is increased risk of infection transmission and in some 
cases a paradoxical worsening of HAE has been observed.
Cinryze
The plasma-derived C1-INH replacement product, Cinryze, 
was approved in the US in 2008 for routine prophylaxis in 
adolescent and adult patients. It is produced by   Viropharma, 
Inc. (Exton, PA) in partnership with the Sanquin Blood 
  Supply Foundation. Sanguin produces a similar product 
known as Cetor®, which has been on the market in the 
Netherlands for 11 years. Cinryze is unique in that it is 
pasteurized and nanofiltered C1-INH from pooled plasma 
of US donors. The nanofiltration step offers protection 
against nonenveloped viruses and prions.31,32 It is dosed twice 
weekly for long-term prophylaxis. To date, the only C1-INH 
  replacement product approved for prophylactic use of HAE 
in the US is Cinryze.
Berinert P
Berinert P was approved in 2009 in the US to treat acute 
abdominal and facial attacks in adolescents and adults 
and is currently approved in 28 countries worldwide.38 It 
is a purified human C1-INH, prepared by CSL Behring 
(Marburg, Germany) from the pooled plasma of US 
donors. There are also published reports demonstrating 
effectiveness of long-term prophylaxis with Berinert P.39 
Berinert P is considered very safe to use and is adminis-
tered intravenously.
ecallantide
Ecallantide was approved in 2009 in the US to treat 
acute peripheral, abdominal, and laryngeal attacks in 
patients $16 years old (it is currently awaiting approval in 
Europe).40 It is manufactured by Dyax (Cambridge, MA). The 
drug inhibits plasma kallikrein, a serine protease involved 
in the breakdown of high-molecular-weight kininogen to 
bradykinin, and is an even more potent and selective inhibi-
tor of kallikrein than C1-INH.41 It is a recombinant product 
and therefore free of human or animal contaminants. It is 
administered via subcutaneous injections.42 Ecallantide is 
well tolerated but has been associated with a 3.9% inci-
dence of anaphylaxis during clinical trials. For this reason, 
an immunogenicity trial is to determine the ongoing risk of 
developing specific IgG and IgE antibodies and anaphylaxis 
with repeated use.43
Experimental therapies for HAE
New therapies, icatibant and conestat alfa, are under con-
sideration for FDA approval for use in the US but have been 
approved for use in Europe. There continues to be a need for 
further investigation into both acute, short-term and long-
term prophylactic treatment of HAE as well as other potential 
indications for these agents. For example, despite long-term 
prophylaxis, breakthrough angioedema attacks still occur in a 
significant number of patients. This has led to a dose escalating 
trial for Cinryze to determine the maximum safe dose required 
to prevent breakthrough attacks. In addition, the potential 
adverse effects of approved treatments (ie, anaphylaxis reports 
with ecallantide) have significantly limited their use.44Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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icatibant
Clinical trials have now been completed for Icatibant in the 
US and it is awaiting FDA approval however, it is currently 
available in several European countries.45 It is manufactured 
by the German company Jerini (Berlin, Germany). The drug 
is a synthetic decapeptide, similar in structure to bradykinin, 
which functions as a highly specific and extremely potent 
antagonist of the bradykinin receptor, BK2R. Icatibant is 
resistant to the proteolytic effects of carboxypeptidase-N and 
angiotensin converting enzyme, which degrade bradykinin.46 
It is delivered in a subcutaneous form.
Conestat alfa
introduction to the drug
Over the last decade the management of HAE has been dra-
matically changing. Biotechnical advances have allowed the 
emergence of numerous C1-INH replacement options that 
expand the ability to individualize treatment. Human C1-INH 
is a plasma serine protease inhibitor that inhibits proteases 
in the coagulation/fibrinolytic system (factor XII, factor XI, 
thrombin, plasmin, and tissue plasminogen activator), the 
complement system (C1r, C1s, MASP-1, and MASP-2), and 
the kinin system (kallikrein) (Figure 1).47 Plasma-derived 
C1-INH has been used to treat acute HAE attacks since 
the 1970s and has dramatically improved the outcome of 
laryngeal attacks in these patients in countries where it has 
been readily available.48,49 In 1996, the first double-blind, 
placebo-controlled trials documenting the efficacy of C1-INH 
replacement in both acute attacks and prophylaxis were 
reported.39 Attempts to clone C1-INH in multiple cellular 
expression systems has resulted in severe alterations in its 
protein expression or conformation.50–53 In order to address 
the need for a readily available supply of C1-INH that was not 
dependent on plasma donations, the Dutch company Pharming 
(Leiden, the Netherlands) developed conestat alfa, a recombi-
nant human C1-INH made from the breast milk of transgenic 
  rabbits. Conestat alfa is being marketed under the brand name 
Rhucin in the US and Ruconest in Europe. The production 
techniques utilized to make conestat alfa have resulted in a 
highly purified, large quantity of functionally active product 
with extremely low risk of pathogen   transmission. The drug 
has a purity level of 99.98%, with ,20 ppm of contaminants. 
Phase I, II, and III clinical trials have now been completed 
in Europe and the US. It has been approved in Europe under 
the name Ruconest, but approval in the US under the name 
Rhucin is still pending the results of a supplemental clinical 
trial currently in progress.54
Biochemical structure and function
The C1-INH gene is on chromosome 11 and consists of 
8 exons and 7 introns. The protein consists of 500 amino 
acids.55 C1-INH exists in plasma as a heavily glycolated 
single-chain protein of 478 amino acids and weighs 105 kDa, 
of which approximately 50% is carbohydrate. Conestat alfa 
is a human plasma protease C1-INH, recombinant protein 
expressed in the mammary gland of transgenic rabbits, 
also consisting of 478 amino acids, though it weighs less 
(67,000 kDa) than human C1-INH due to less glycosylation.56 
The N-glycans of conestat alfa are under-sialylated, whereas 
its O-glycans are   over-sialylated.57 Functionally, conestat 
alfa, compared with human C1-INH, is similar in its ability 
to inhibit C1, plasma kallikrein, factor XIa, and factor XIIa. 
Though it appears that differential glycosylation of conestat 
alfa relative to the human protein decreases the half-life to 
approximately 3 hours, this does not seem to be relevant 
clinically.2 Since N-linked glycosylation is important for 
the three-dimensional structure of protein, this process was 
studied in conestat alfa. It was demonstrated that the major 
N-glycan structures on conestat alfa were similar to those 
of human C1-INH, but sialylation levels decreased with 
progression of lactation.58
Pharmacology
Because C1-INH is the only known inhibitor of the classical 
arm of the complement pathway, in HAE, replacement of 
C1-INH decreases the baseline consumption of C4 in asymp-
tomatic patients (Table 1). Hence, the pharmacodynamics of 
conestat alfa were analyzed by measuring C4 concentration 
and degradation in asymptomatic HAE patients. Conestat 
alfa exhibited dose-dependent activity both by increasing 
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Figure 1 Sites of C1-inhibitor (C1-iNH) regulation of the contact, complement, 
and fibrinolytic systems.  Conestat alfa, a recombinant C1-INH, likely regulates the 
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C4 levels and decreasing C4b/c. During HAE attacks, the 
C4 level peaked at 24 hours and continued to be elevated out 
to Day 22.59 Pharmacokinetic analysis revealed that C1-INH 
levels were elevated to twice normal levels for 2 hours and 
remained greater than the critical activation level of 0.4 U/mL 
for approximately 9 hours (Table 2).60 With doses ranging from 
6.25 U/kg–100 U/kg of conestat alfa in asymptomatic patients, 
both maximum function of C1-INH (Cmax) and the duration 
of C1-INH serum level above 0.4 U/mL exhibited a dose-
dependent increase, with ranges of 0.32 U/mL–2.46 U/mL 
and 9.1–549.7 min, respectively. During attacks in which 
patients were treated with 100 U/kg of conestat alfa, the Cmax 
was 3.8 ± 0.8 U/mL versus 2.5 ± 0.2 U/mL in asymptomatic 
patients treated with the same dose.61 The dose-normalized 
Cmax was constant (P = 0.48), suggesting dose proportional-
ity, but clearance ranged from 71.4 to 12.7 mL/min and the 
elimination half-life ranged from 28 to 172 minutes depending 
on the dose. The pharmacokinetic data fit a 1-compartment 
model based on Michaelis–Menten kinetics and demonstated 
dose independence for maximum enzymatic activity (Vmax), 
which is 45 U/minute, and the volume of distribution, which 
is 3.3 L. The Michaelis–Menten constant is 0.57 U/mL.62
Conestat alfa is freeze-dried and free of preservatives. 
One unit corresponds to the quantity of C1-INH present 
in 1 mL of normal fresh plasma. Conestat alfa contains 
2100 units per vial after reconstitution in 14 mL of diluent 
and is administered intravenously. The maximum dose is 4200 
U for patients with body weight $84 kg. It is recommended 
that no more than two intravenous injections be administered 
within any 24-hour period.
Safety
No drug-related adverse events or clinically relevant vital 
sign changes, ECG findings, or laboratory abnormalities 
(including hematological, biochemical, and coagulation, 
viral serology, and anti-C1-INH and antibodies against rabbit 
milk protein) have been reported in clinical trials. The most 
common side effect is headache.
Blood samples from 137 HAE patients with a total of 
322 treatments with conestat alfa for acute HAE attacks were 
tested for infectious transmission and antibodies in clinical 
studies. Fourteen patients had received conestat alfa for at 
least five acute angioedema attacks with up to 20 treatments 
in one patient.63 Transmission of rabbit or human viruses have 
not been observed.61,62,64 
The frequency and amplitude of anti-conestat alfa IgG 
and IgM results in pretreatment versus post-  treatment sam-
ples was similar, suggesting no effect of antibody generation 
with treatment. Positive samples did not have any detectable 
neutralizing antibodies. For possible antibody formation 
against host-related impurities (HRI), positive anti-HRI 
results were slightly higher for postexposure samples, but 
with repeated treatment there were no clinically relevant 
adverse events in these patients. In addition, these anti-HRI 
responses did not persist.
One hundred thirty-seven healthy volunteers and HAE 
patients were tested for the presence of IgE antibodies against 
four rabbit allergens and 10 other animal allergens after their 
last exposure to conestat alfa. Twenty-four out of 137 (17.5%) 
subjects had at least one positive IgE antibody test result 
at baseline. Five subjects had a positive test against rabbit 
allergens. Three of the five subjects positive for IgE against 
rabbit allergens reported allergic symptoms after conestat 
alfa exposure.65 One healthy volunteer, who did not disclose 
a history of rabbit allergy and with the highest rabbit dander-
specific IgE level (39 kU/L), had an anaphylactic reaction 
after the first exposure to conestat alfa. This has been the 
only severe allergic reaction to date.2,62,65,66 Three subjects 
Table 2 Pharmacokinetics of conestat alpha
Baseline serum  
C1-INH  
concentration  
(U/mL)
Maximum  
concentration  
(Cmax, U/mL)
Dose normalized  
maximum  
concentration  
(U/mL/U/kg)
Time above critical  
concentration of  
0.4 U/mL (min)
Clearance  
(mL/min)
Volume of  
distribution (L)
Half-life  
(min)
Maximum 
enzymatic 
activity 
(Vmax)
0.18 (0.12) 1.36 (0.31) 0.0236 (0.00468) 314.5 (210.3) 22.8 (7.3) 3.03 (0.79) 93.7 (8.5) 46.9 (14.97)
Table 1 Pharmacodynamics of C4 in asymptomatic hereditary angioedema patients
Baseline serum  
concentration
Maximum  
concentration  
(Cmax, %)
Time of maximum  
concentration  
(Tmax, mins)
Minimum  
concentration  
(Cmin, %)
Time of minimum   
concentration  
(Tmin, mins)
C4 538.7 (184.37) 175.5 (81.93) 640.0 (123.94) 80.0 (2.05) 35.5 (20.11)
C4b/c 107.4 (58.51) 5.3 (1.90) 40.3 (39.63)Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
270
Davis and Bernstein
had pre-existing IgE against cow milk, but none developed 
allergic-type symptoms on exposure to milk-derived conestat 
alfa. After treatment, none of the 24 subjects with pre-existing 
IgE had an increase in IgE levels to rabbit or cow milk 
allergens. One subject after exposure developed IgE against 
cow milk allergens, but not against rabbit allergens. Another 
subject developed IgE against rabbit meat. Neither of these 
two subjects developed allergic symptoms with conestat alfa 
exposure.65 Excluding antirabbit IgE in patients is advised 
before use of conestat alfa.
Efficacy
In two open-label, clinical studies on nine HAE patients who 
were treated with conestat alfa for 13 angioedema attacks, 
symptoms of attacks were assessed both by the physician and 
by the patients using visual analog scales (VAS, Table 3). 
These studies demonstrated that the median time to onset 
of symptom relief was ,60 minutes, whereas median 
time to minimal symptoms was ,8 hours.61 VAS scores 
for symptoms of peripheral attacks were obtained from 65 
patients in all clinical trials. Treatment with conestat alfa 
significantly decreased the duration of swelling, pain and 
associated dysfunction of peripheral angioedema attacks in 
HAE patients.67
Two separate randomized, double blind, placebo-
  controlled clinical trials showed median time to the 
beginning of symptom relief and median time to minimal 
symptoms was significantly improved with conestat alfa. 
Patients were randomized to receive conestat alfa 100 U/kg, 
50 U/kg, or   placebo. For the 100 U/kg, 50 U/kg, and placebo 
doses, patients reported onset of symptom relief at a median 
of 68 minutes, 122 minutes, and 258 minutes, respectively 
and time to minimal clinical symptoms of 245, 247, and 
1098   minutes, respectively. These results were statistically 
significant relative to placebo with P values ,0.01.64,68 All 
attacks treated with conestat alfa abated, without evidence 
of acute recurrence or rebound, defined as an increase in 
the VAS to the patient’s baseline score or greater after 
experiencing some relief within 4 hours after receiving 
the drug.64
To obtain further evidence about the safety and efficacy 
of conestat alfa, particularly with repeated dosing for recur-
rent attacks, open-label extensions were included as a part 
of the randomized studies. Sixty-five patients were treated 
with conestat alfa doses ranging from 2100 U to 100 U/kg. 
The median time to onset of relief and median time to mini-
mal symptoms was similar to the randomized trial results. Of 
note,   treatment was effective independent of the   anatomical 
location. Although all doses of conestat alfa used in the open-
label extensions were effective, the 2100 U dose appeared to 
be less effective.67,68
Conestat alfa appears to be safe with no reduction in 
effectiveness in patients receiving up to 26 treatments. 
Therapeutic failure, defined as time to onset of relief 
occurring after 4 hours, relapse within 4 hours, or the use 
of additional medication to treat the attack was reported 
in 11% and 10% of attacks treated with 50 and 100 U/kg, 
respectively, compared with 17% for the 2100 U dose.68 
The percentage of HAE attacks responding to 50 U/kg and 
100 U/kg doses of conestat alfa within 4 hours was 92% 
and 93%, respectively, compared with 41% with placebo. 
Thus there appears to be no significant difference between 
the 50 U/kg and 100 U/kg doses. In addition, a computer 
simulation with a population pharmacokinetic model 
based on data from 214   administrations of conestat alfa in 
120 patients demonstrated that doses of 50 U/kg brought 
functional C1-INH levels into normal range (.0.7 U/mL) 
in almost all patients and above the critical activation level 
(0.4 U/mL) in all patients.68 Therefore, since no further 
improvement was achieved with a dose of 100 U/kg, the 
50 U/kg dose is the recommended dose for the treatment 
of acute HAE attacks with conestat alfa.
Table 3 Summary of safety and efficacy trials
Treatment doses Subjects Efficacy results Safety results
Phase ii
100 U/kg within  
8 hours of attack  
onset
9 subjects with  
13 severe attacks
80% achieved symptom relief in 2 hours and minimal  
symptoms by 12 hours
No drug-related  
adverse events or  
immunogenic reactions
Phase iii
Time to symptom  
relief (min)
Time to minimal  
symptoms (min)
Treatment  
failure
No postexposure  
antibody response  
against either rhC1-iNH  
or rabbit-related impurities
Saline n = 29 495 1220 59%
50 U/kg n = 12 122 247 0%
100 U/kg n = 29 66 266 10%*
Note: *The larger 95% Ci of the odds ratios for the 50 U/kg group compared with that for the 100 U/kg group suggests no real difference in the percentage of therapeutic 
failures in either treatment group, which is in agreement with open label data.Therapeutics and Clinical Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Current commercial status
Conestat alfa has been approved by the European Medicines 
Agency and is now available in several European countries. 
The FDA has delayed its approval in the US as it felt that 
additional therapeutic and safety analyses were necessary, 
which are currently ongoing.
Conclusion
In the past few years multiple C1-INH replacement products 
have been approved for the treatment of both acute HAE 
attacks and long-term prophylaxis. Conestat alfa is unique 
from other products as it is being produced from transgenic 
rabbits, which can provide a potentially unlimited source 
drug, which obviates the need for collecting plasma or any 
concerns about infectious transmission from human donors. 
In summary, the clinical trials to date demonstrate that con-
estat alfa is safe and effective for treatment of HAE attacks, 
independent of the anatomic location. Symptoms quickly 
respond (1 hour vs 8 hours) and resolve (6 hours vs 20 hours) 
with treatment. Unless there was a prior sensitization to rabbit 
allergens, no significant adverse events such as anaphylaxis 
have been reported. There were no laboratory abnormalities 
and no acute relapses or rebound attacks observed. The dose of 
50 U/kg appears to be the lowest effective dose for treatment. 
No additional therapeutic benefit has been observed by using 
higher doses. Finally, no decrease in effect has been reported 
with repeated doses.
Conestat alfa appears to have the same biologic and clini-
cal effect as human C1-INH. Because C1-INH concentrate is 
safe and effective for pediatric and pregnant patients,69 given 
the similar biological profile of conestat alfa to its human 
counterpart, it would also likely be safe and effective for 
these populations, but additional studies to confirm these 
indications have yet to be done.
In that plasma-derived C1-INH has been investigated as a 
therapy for indications other than HAE such as sepsis, acute 
myocardial infarction, cardiopulmonary bypass surgery, and 
ACE-inhibitor induced angioedema, further investigations 
are warranted to determine whether conestat alfa would also 
be effective for these indications.70–73
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